|
|||||
|
|
| 吉西他滨联合铂类治疗64例晚期非小细胞肺癌临床疗效研究 | |
| 引用本文： | 姚成才,林丛尧,安公明.吉西他滨联合铂类治疗64例晚期非小细胞肺癌临床疗效研究[J].现代肿瘤医学,2007,15(11):1600-1602. |
| 作者姓名： | 姚成才 林丛尧 安公明 |
| 作者单位： | 1. 福建中医学院附属厦门中医医院胸外科,福建,厦门,361000 2. 武汉大学中南医院肿瘤科,湖北,武汉,430071 3. 武钢大冶铁矿医院胸外科,湖北,大冶,435006 |
| 摘 要： | 目的:比较吉西他滨(gemcitabine)联合顺铂(cisplatin)、卡铂(carboplatin)和奥沙利铂(oxaliplatin)三种化疗方案对晚期非小细胞肺癌(NSCLC)的疗效和毒性反应。方法:经病理和细胞学证实的64例晚期NSCLC患者随机分为吉西他滨 顺铂(gemcitabine cisplatin,Gcis)、吉西他滨 卡铂(gemcitabine carbopl-atin,Gcarb)和吉西他滨 奥沙利铂(gemcitabine oxaliplatin,GLOHP)三组。三组均选用吉西他滨1000mg/m2静脉滴注第1、8天。GCis组:顺铂70mg/m2静脉滴注,第1天;GCarb组:卡铂AUC4～6(初治6,复治4～5),静脉滴注,第1天;GLOHP组:奥沙利铂LOHP130mg/m2静脉滴注,第1天。三组均21天为一周期,连续使用2～3周期评价疗效和毒副反应。结果:Gcis、Gcarb、GLOHP三种方案治疗晚期非小细胞肺癌的有效率分别为52.38%(11/21)、50.00%(10/20)和60.87%(14/23)(P>0.05)。三种方案毒副反应主要为可耐受的骨髓抑制、消化道反应、脱发和外周神经毒性等。结论:吉西他滨联合三种不同铂类的化疗方案均为治疗晚期非小细胞肺癌较为安全有效的化疗方案。 |
| 关 键 词： | 非小细胞肺癌 化学治疗 吉西他滨 顺铂 卡铂 奥沙利铂 |
| 文章编号： | 1672-4992-（2007）11-1600-03 |
| 修稿时间： | 2006-12-31 |
A clinical study on efficacy of gemcitabine combined with platin treated 64 cases advanced non- small cell lung cancer |
|
| YAO Cheng-cai,LIN Gong-yao,AN Gong-ming.A clinical study on efficacy of gemcitabine combined with platin treated 64 cases advanced non- small cell lung cancer[J].Journal of Modern Oncology,2007,15(11):1600-1602. | |
| Authors: | YAO Cheng-cai LIN Gong-yao AN Gong-ming |
| Institution: | 1 Department of Chest surgery, Fujian Traditional Chinese Medical College Affiliated Xiamen T. C. M Hospital,Xiamen 361000, Chi na ; 2 Oncology Department, Zhongnan Hospital of Wuhan University, Wuhan 430071, China;3 Wuhan Steel Corporation affiliated Daye I ron Hospital, Daye 435006, China. |
| Abstract: | Objective:To observe the efficacy and toxicity of gemcitabine plus cisplatin,carboplatin and oxaliplatin in the treatment of advanced non-small cell lung cancer(NSCLC).Methods:Sixty-four patients with histologically confirmed NSCLC were randomized to enter the study.Gemcitabine 1 000 mg/m2iv-drop on day1,8 in gemcitabine cisplatin(Gcis),gemcitabine carboplatin(Gcarb)and gemcitabine oxaliplatin(GLOHP)three groups;GCis group:cisplatin 70 mg/m2iv-drop on day 1;GCarb group:carboplatin AUC 4~6 iv-drop on day 1.GLOHP group:oxaliplatin 130mg/m2iv-drop on day 1.Results:The response rates were 52.38%(11/21),50.00%(10/20)and 60.87%(14/23)in GCis group,GCarb group and GLOHP group respectively(P>0.05).Toxicities included myelosuppression,digestive reaction,alopecia and neurotoxicity and so on.Conclusion:Gcis,GCarb and GLOHP three chemotherapeutic projects are all effective and safe for the treatment of advanced NSCLC patients. |
| Keywords: | non-small cell lung cancer chemotherapy gemcitabine cisplatin carboplatin oxaliplatin |
| 本文献已被 CNKI 维普 万方数据 等数据库收录！ | |